SAREPTA THERAPEUTICS, INC.

Lobbying for SAREPTA THERAPEUTICS, INC.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 15, 2025

Expenses

$430,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 4

Health Issues

Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases

Pharmacy

Issues related to the Inflation Reduction Act's prescription drug provisions

Science/Technology

Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance

Taxation/Internal Revenue Code

Tax issues related to research and development

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.